Serum CXCL10 levels are associated with better responses to abatacept treatment of rheumatoid arthritis

K. Yukawa[1,2], S. Mokuda[1], H. Kohno[1], K. Oi[1], T. Kuranobu[1], T. Tokunaga[1], Y. Yoshida[1], J. Yamana[2], M. Iwahashi[2], S. Hirata[1], S. Yamana[2], E. Sugiyama[1]

[1]Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan; [2]Division of Arthritis and Collagen Disease, Higashi-Hiroshima Memorial Hospital, Higashi-Hiroshima, Japan.

Abstract

Objective

This study aimed to identify therapeutic predictors of abatacept (ABT) treatment in rheumatoid arthritis (RA) in vitro and in patients.

Methods

T cell cytokine, monokine, and chemokine levels in culture supernatants or serum were determined using flow cytometry bead-based immunoassays. CXCL10 mRNA and protein expressions were also assessed using qPCR and ELISA analyses, respectively. In the patient study, 25 ABT-treated patients were analysed retrospectively. The patients were divided into low disease activity (LDA) or non-low disease activity (non-LDA) groups at 24 weeks of ABT treatment. Seven T cell cytokines and CXCL10 levels were compared in these two groups.

Results

Peripheral blood mononuclear cells (PBMC) from healthy donors were stimulated by immobilised anti-CD3 with or without ABT for three days, and the levels of 13 T cell cytokines in culture supernatants were determined. ABT significantly inhibited anti-CD3-induced production of IFN-γ. To examine the effect of these T cell cytokines in rheumatoid synovial cells (RSC), RSCs were stimulated with 10% of culture supernatants from anti-CD3-stimulated PBMCs with or without ABT, and the levels of 23 cytokines were determined. Only CXCL10 was significantly reduced by ABT-treated supernatants. In the patient study, CXCL10 levels at baseline were not different between the LDA and non-LDA groups, whereas CXCL10 levels at 24 weeks were significantly decreased in the LDA group only.

Conclusion

ABT treatment significantly affected IFN-γ and CXCL10 cytokine levels in vitro. In addition, serum CXCL10 levels were associated with better responses in ABT treatment.

Key words

rheumatoid arthritis, abatacept, C-X-C motif chemokine 10 (CXCL10), cytokine

Kazutoshi Yukawa, MD
Sho Mokuda, MD, PhD
Hiroki Kohno, MD
Katsuhiro Oi, MD, PhD
Tatsuomi Kuranobu, MD
Tadahiro Tokunaga, MD
Yusuke Yoshida, MD, PhD
Jiro Yamana, MD, PhD
Mitsuhiro Iwahashi, MD, PhD
Shintaro Hirata, MD, PhD
Seizo Yamana, MD, PhD
Eiji Sugiyama, MD, PhD

Please address correspondence to:
Eiji Sugiyama,
Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, 1-2-3, Kasumi, Minami-ku, Hiroshima 734-8551, Japan
E-mail: esugiyam@hiroshima-u.ac.jp

Received on August 19, 2019; accepted in revised form on November 4, 2019.

Funding: this work was supported by JSPS Kakenhi grant no. 19K08908 to E. Sugiyama, 19K18499 to S. Mokuda and 19K07940 to S. Hirata.

Competing interests: E. Sugiyama and S. Hirata have received speakers fees from Bristol-Myers Squibb. The other co-authors have declared no competing interests.

Introduction

Rheumatoid arthritis (RA) is an autoimmune disease characterised by synovitis, autoantibody production, cartilage and bone destruction, and systemic inflammation, and its development is associated with genetic and environmental factors (1, 2). The current treatment approach in RA follows a stepwise management, starting from conventional synthetic disease-modifying anti-rheumatic drugs (DMARDs) to biological DMARDs and targeted synthetic DMARDs (3, 4).

Abatacept (ABT), a fully soluble fusion protein, consists of the extracellular domain of human cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) linked to the Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 that has been modified to avoid complement fixation. Mechanistically, ABT exerts its action by inhibiting the CD80/CD86:CD28 pathway, a key costimulatory pathway required for full T cell activation (5). When administered alone or in combination with MTX, ABT has been shown to significantly improve the signs and symptoms of RA, joint destruction, and health-related quality of life (6, 7).

However, ABT treatment is costly and fails to produce a response in a substantial proportion of patients. For example, in more than 20 % of RA patients treated with high doses of biologics, including ABT, treatment was ineffective according to Japanese post-marketing surveillance (8). As such, a personalised therapeutic approach is desirable to reduce periods of disease activity and patient exposure to the potential side effects of an ineffective treatment (4). Several studies have reported on the usefulness of clinical and laboratory variables, autoantibodies, cytokines, T cell subsets, and genetic factors as predictors of treatment response to ABT (7, 9-14). However, a clinically useful biomarker for ABT treatment remains to be identified.

Tweehuyseb *et al*. (15) reported that a number of cytokines, which are inhibited by biologics *ex vivo*, show some predictive value for drug treatment, suggesting that *ex vivo* or *in vitro* experiments using biologics may be good tools for identification of the corresponding treatment biomarkers. We hypothesised here that cytokines and chemokines, with substantial ABT-induced suppression *in vitro*, would be good predictors of ABT treatment response in RA. In this study, we first identified cytokines and chemokines that were most suppressed by ABT in anti-CD3-stimulated peripheral blood T cells or rheumatoid synovial cells culture *in vitro*. Second, we analysed RA patients treated with ABT and examined the relationship between serum cytokine levels affected by ABT *in vitro* and disease activity, including achievement of low disease activity (LDA) and disease activity score (DAS28-CRP) <2.7 at 24 weeks.

Materials and methods

In vitro T cell activation and measurement of T cell cytokines

The *in vitro* study was approved by the Institutional Research and Ethics Committee of Hiroshima University (E-668-1), and written informed consent was obtained from all healthy donors and patients with RA. Mononuclear cells from the peripheral blood of 10 healthy donors were separated by Lympholyte®-H (Cedarlane, NC, USA) density gradient centrifugation. A 96-well microplate was pretreated with 50 μL of 10 μg/mL anti-CD3 (clone OKT3, BioLegend, San Diego, CA, USA) for 2 h. After washing with phosphate-buffered saline (PBS), peripheral blood mononuclear cells (PBMC) were cultured at a cell density of 2×10^5 cells/well in 96-well tissue culture plates with or without ABT (Orencia®, Bristol Myers Squibb Co.) for 3 days. The concentration of ABT used in this study was 500 μg/ml, which is the maximum blood concentration during ABT treatment. T cell cytokines, including TNF-α, IL-2, IL-4, IL-5, IL-6, IL-9, IL-10, IL-13, IL-17A, IL-17F, IL-21, IL-22, and IFN-γ levels, in the culture supernatants were then determined by a flow cytometry bead-based immunoassay (LEGENDplex™ Human T Helper cytokine panel, BioLegend) using a CytoFLEX flow cytometer (Beckman Coulter Co.) according to the manufacturer's instructions.

Preparation of rheumatoid synovial cells (RSC) and measurement of cytokines and chemokines in RSC culture

Synovia were obtained from three RA patients by surgical treatment after receiving written informed consent. The three patients with RA who provided synovial membranes were all women with a mean age of 63 (51-85) years and IgM-RF-positive and anti-CCP-positive results. These patients were all treated with csDMARDs (two patients with methotrexate, one patients with leflunomide) without biologics. In the disease activity based on the DAS-28 score, one patient had high activity and two patients had low activity. Rheumatoid synovium was obtained by surgical treatment of total knee arthroplasty. Isolated rheumatoid synovia were aseptically dissected free from the surrounding tissues, minced, and enzymatically digested with 1–2 mg/mL clostridium collagenase (Wako Pure Chemical Industries, Ltd, Osaka, Japan) and 5–10 μg/mL deoxyribonuclease 1 (Sigma Chemical Co., St Louis, MO) for 2–3 h at 37°C. After digestion, the resulting single cell suspension was washed, filtered through sterile gauze and nylon mesh, washed thoroughly again, and finally resuspended in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% heat inactivated fetal calf serum. Subsequently, the cells were cultured overnight to adhere to the culture plate. After the plate was washed to remove non-adherent cells, the remaining adherent cells were used as RSCs. The rheumatoid synovial cells used in this study were all CD14-negative, suggesting that they were fibroblast-like cells, not macrophages. To evaluate the effect of anti-CD3-stimulated T cell cytokines, RSC were cultured with 10% of culture supernatants of anti-CD3-stimulated PBMC from healthy donors with or without ABT for 3 days. The cytokine and chemokine levels in the culture supernatants were determined by a flow cytometry bead-based immunoassay (LEGENDplex™ Human macrophage panels and human proinflammatory chemokine panel) using a CytoFLEX flow cytometer according to the manufacturer's instructions. The cytokines and chemokines measured in these experiments were as follows: TNF-α, IL-1β, IL-1RA, IL-4, IL-6, IL-8, IL-10, IL-12p40, IL-23, IFN-γ, arginase, C-C motif chemokine (CCL)2, CCL3, CCL4, CCL5, CCL11, CCL17, CCL20, CXCL1, CXCL5, CXCL9, CXCL10, and CXCL11.

Quantitative real-time PCR and ELISA analyses for CXCL10 expression

• *qPCR analysis of CXCL10*

RSCs were cultured with IL-1β, TNF-α, IL-6, IL-6 receptor α (Rα), IL-17A (all from BioLegend), or IFN-γ (Peprotech Inc, Rocky Hill, NJ, USA) for 24 h. After culture, treated RSCs were lysed, and total RNA was isolated using a NucleoSpin® RNA kit (Takara-Bio, Japan). Subsequently, total RNA (200 ng) was reverse transcribed to cDNA using a PrimeScript™ RT reagent Kit with gDNA Eraser (Takara-Bio, Japan). Real-time RT-PCR was then performed using TB Green™ *Premix Ex Taq*™ II (Tli RNaseH Plus) (Takara-Bio, Japan) with the CFX Connect Real-Time PCR Detection System (Bio-Rad Laboratories, Inc). PCR amplification was performed with 40 cycles at 95°C for 5 s and 60°C for 10 s. The following primes were used: CXCL10 (sense, 5'-AAAGCAGTTAGCAAGGAAAG-3' and antisense, 5'-TCATTGGTCACCTTTT-3'); β-actin (sense, 5'-GACGACATGGAGAAAATCTG-3' and antisense, 5'-ATGATCTGGGTCATCTTCTC-3'). CXCL10 sense mRNA expression was normalised to β-actin for each sample.

• *ELISA assay for CXCL10*

RSCs were incubated with the indicated cytokines for 48 h. After culture, CXCL10 levels in the culture supernatant were determined using an ELISA kit (BioLegend) according to the manufacturer's instructions.

Patient study

This study retrospectively analysed data from 25 patients diagnosed with RA between September 2010 and April 2017 who received intravenous ABT treatment. All patients fulfilled the 2010 European League against Rheumatism (EULAR) and American College of Rheumatology (ACR) classification criteria for RA (16, 17). This study followed the guidelines of Helsinki Declaration and ethical guidelines for epidemiologic research in Japan. The study protocol was approved by the Institutional Ethical Committee of Higashi-Hiroshima Memorial Hospital (permission; HMH-18-01) and Hiroshima University (permission; E-1383). ABT was introduced through intravenous infusion according to baseline weight (<60 kg received 500 mg, 60–100 kg received 750 mg, and >100 kg received 1000 mg) on days 1, 15, and 29, followed by monthly treatments. The same doctor at Higashi Hiroshima Memorial Hospital determined the clinical outcome of all patients at week 24 to potentially eliminate bias. Evaluation of clinical disease activity in patients was conducted by assessing the following parameters: C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), matrix metalloproteinase 3 (MMP-3), rheumatoid factor (RF), anti-CCP antibody, tender joints count, swollen joints count, and DAS28-CRP. Serum samples collected from patients were immediately stored at -20°C. Serum levels of IL-2, IL-17A, TNF-α, and CXCL10 were assessed by a flow cytometry bead-based immunoassay according to the manufacturer's instructions (LEGENDplex, BioLegend). IL-4, IL-6, IL-10, and IFN-γ levels were assessed using ELISA kits (Biolegend).

Statistical analyses

The values in Figures 1 and 2 are displayed as mean ± SE. The values in Figure 3 are displayed as mean ± SD. The values in the tables are expressed as median (interquartile range), number, or percentage. The differences between pairs of groups were compared using unpaired t-test, Mann-Whitney U, or Wilcoxon's rank test. Categorical variables were analysed using Fisher's exact test or the χ^2 test, $p<0.05$ was considered to be statistically significant. All analyses were performed using the statistical software package EZR (Easy R) (Jichi Medical University Saitama Medical Center, Saitama, Japan), v. 1.30, which is based on R and R commander.



Fig. 1. The effects of abatacept (ABT) on T cell cytokine production by anti-CD3 stimulated peripheral blood mononuclear cells (PBMC).
PBMCs were cultured on immobilised monoclonal anti-CD3 pre-coated microplates with or without ABT (500 μg/mL) for 3 days, and T cell cytokine levels in cultured supernatants were analysed using flow cytometry bead-based immunoassays. Data below the lower limit of detection were regarded as 50% of the lower limit in some samples.
The results are shown as the mean ± SE (n=10). *p<0.05, **p<0.01.



Fig. 2. The effect of abatacept (ABT)-treated PBMC culture supernatant on monokine and chemokine production by rheumatoid synovial cells (RSC).
PBMCs were cultured on immobilised monoclonal anti-CD3 pre-coated microplates with or without ABT (500 μg/mL) for 3 days. The culture supernatants were added to the RSC culture at a final concentration of 10% for 48 h. The levels of 23 monokines and chemokines in the culture supernatants were determined using flow cytometry bead-based immunoassays. The net concentrations of each cytokine were obtained by subtracting the values of the cell-free supernatant from those of the RSC culture supernatant. The results are shown as the mean ± SE (n=10). * p<0.05.



Fig. 3. The effect of inflammatory cytokines on CXCL10 expression in RSC culture.
A: Rheumatoid synovial cells (RSC) were cultured with inflammatory cytokines, including IL-1β (50 ng/mL), TNF-α (50 ng/mL), IL-6 (50 ng/mL), IL-6 receptor α (50 ng/mL), and IFN-γ (50 ng/mL), or in combination for 24 h. Total cellular RNA was then extracted and analysed using real-time PCR with the CXCL10 mRNA primer set. The data were normalised to β-actin (n=2).
B: RSCs were cultured with inflammatory cytokines, including IL-1β (50 ng/mL), TNF-α (50 ng/mL), IL-6 (50 ng/mL) with IL-6 receptor α (50 ng/mL), IL-17A (50 ng/mL), and IFN-γ (50 ng/mL), or in combination for 48 h, and CXCL10 levels in the cultured supernatants were analysed using ELISA assays. The results are shown as the mean ± SD (n=3). $^{**}p<0.01$.

Results

Effects of ABT on T cell cytokine production by anti-CD3-stimulated PBMC

To determine which T cell cytokines are most reduced by ABT *in vitro*, we evaluated the effect of ABT on anti-CD3-induced production of T cell cytokines in PBMC culture. As shown in Figure 1, ABT significantly inhibited IL-4, IL-9, IL-10, IL-13, IL-17A, IL-17F, and IFN-γ production. Among which, IFN-γ was most significantly inhibited by ABT (Fig. 1).

Effect of ABT-treated PBMC culture supernatant on monokine and chemokine production by RSCs

Several T cell cytokines has been reported to modulate production of pro-inflammatory cytokines by RSCs. Therefore, we first cultured PBMCs in anti-CD3 pre-coated microplates with or without ABT for 3 days. Subsequently, their supernatants were added to the RSC culture at a final concentration of 10%. After culture for 48 h, the levels of inflammatory cytokines and chemokines in the supernatant were determined. Among 23 cytokines tested, only CXCL10 was significantly inhibited by ABT (Fig. 2A-B).

Effect of inflammatory cytokines on CXCL10 expression in RSC culture

IFN- γ is known to be a potent inducer of CXCL10 (18) and may mediate ABT-induced inhibition of CXCL10. However, its effect does not exclude the possible involvement of other inflammatory cytokines. Therefore, we examined the effect of inflammatory cytokines on CXCL10 mRNA and protein expression levels in RSC culture. As shown in Figure 3A and B, IFN-γ potently induced CXCL10. In contrast, there were minimal effects by other inflammatory cytokines, suggesting that ABT may primarily affect the IFN-γ/CXCL10 pathway in T cells and RSC culture *in vitro*.

Characteristics of RA patients

Of the 25 study participants, 72% of patients were females, and their median age was 70 (65–73) years, of which 84% and 96% of patients were IgM-RF-positive and anti-CCP-positive, respectively. Among patients with anti-CCP, median levels were 111 U/mL (32.4–264). The median tender joint count, swollen joint count, patient's visual analogue scale, and DAS28-CRP were 6 (3–7), 6 (4–9), 50 (40–70), and 4.9 (4.4–5.3), respectively.

Correlation between candidate predictors and therapeutic response

All patients were intravenously treated with ABT, and treatment response was defined according to the EULAR response criteria of DAS28-CRP score at week 24 after treatment: remission (n=8), low disease activity (n=5), moderate disease activity (n=8), and high disease activity (n=4) (Fig. 4). We divided the study population into two groups: achieved LDA (LDA) group (remission and LDA, n=13) and non-achieved LDA (non-LDA) group (Moderate and high disease activity, n=12). Further, we evaluated clinical usefulness of candidate predictors in these two groups. As shown in Tables I and II, no significant difference between LDA and non-LDA groups was observed in baseline data of clinical features, inflammatory parameters, autoantibodies, and serum levels of T cell cytokines and CXCL10. We next analysed differences in T cell cytokines and CXCL10 levels at baseline and 24 weeks in these two groups. As shown in Table III, significant changes at baseline and 24 weeks were not observed in serum levels of IL-2, IL-4, IL-17A, TNF-α, and IFN-γ of both groups. IL-6 and IL-10 were significantly reduced after ABT treatment; however, this reduction was observed in both LDA and non-LDA groups. Interestingly, CXCL10 was significantly reduced only in the LDA group, but not in the non-LDA group, suggesting that serum CXCL10 levels may be associated with the therapeutic response to ABT.

Discussion

ABT is an effective drug in RA treatment, although there are no clinically useful biomarkers for ABT treatment. In this study, we found that the IFN-γ and CXCL10 pathway was most affected by ABT *in vitro* in T cell and RSC cultures.



Fig. 4. Study design.
A: Changes in DAS28-CRP values during the 24-week study of patients treated with abatacept (ABT). The ratios of patients who demonstrated high disease activity (defined as DAS28-CRP >4.1), moderate activity (2.7–4.1), low activity (<2.7), and remission (<2.3) at each observation point at day 0 and week 24 are shown.
B: Patients with ABT treatment were divided into two groups: achieved LDA (LDA) group (remission and LDA, n=13) and non-achieved LDA (non-LDA) group (moderate and high disease activity, n=12), and clinical indices, inflammatory parameters, and autoantibody and serum cytokine levels were compared in the two groups.



Fig. 5. Change in serum levels of IL-6 (A), IL-10 (B), and CXCL10 (C) at day 0 and week 24 in achieved LDA (LDA) and non-achieved LDA (non-LDA) groups. The differences between the two groups were compared using Wilcoxon's rank test. $p<0.05$ was considered to be statistically significant.

In addition, we showed that serum CXCL10 levels are associated with better responses in ABT treatment of RA, although the CXCL10 value at baseline was not different between response and non-response groups. Among 13 cytokines tested, IFN-γ was the most reduced by ABT in the CD3-stimulated PBMC culture. However, IFN-γ was not a suitable predictor and marker of disease activity in ABT-treated patients. In contrast, previous study has reported decreased serum IFN-γ levels in RA patients treated with ABT (19). This discrepancy may be explained by differences in sensitivity of the assay systems used. Scarsi *et al*. (20) demonstrated a reduction in IFN-γ-producing peripheral blood T cells after *in vitro* stimulation in ABT-treated patients, suggesting that the IFN-γ-producing T cell subset would be a good predictor for ABT treatment.

Activation of the inflamed rheumatoid synovium is induced by direct interaction with activated T cells (21). In addition, synovial T cells show similar characteristics as activated human peripheral blood lymphocytes (22). These findings demonstrate the importance of the interplay between RSCs and activated T cells in RA pathogenesis (21). In this study, anti-CD3-stimulated T cells secreted cytokines that induced RSCs to produce large amounts of cytokines and chemokines. ABT-treated

Table I. Baseline characteristics of patients in LDA and non-LDA group.

Characteristic	Whole data (n=25)	LDA group (n=13)	non-LDA group (n=12)	*p*-value
Female, %	72.0	53.8	91.7	0.073[a]
Age, y	70 (65-73)	70 (65-82)	72 (66-89)	0.382[c]
Disease duration, y	6 (2-12)	6 (1.2-14)	5 (2.4-10)	0.913[c]
Stage (I/II/III/IV)	5/8/7/5	3/4/3/3	2/4/4/2	0.918[b]
Class (I/II/III/IV)	0/19/5/1	0/11/2/0	0/8/3/1	0.441[b]
Tender joints count, n	6 (3-7)	6 (2-6)	5 (4-9)	0.527[c]
Swollen joints count, n	6 (4-9)	6 (4-9)	7 (4-9)	0.764[c]
DAS28-CRP	4.9 (4.4-5.3)	4.9 (4.4-5.2)	5.0 (4.3-5.3)	0.785[c]
Dose of MTX, mg/wk	8 (0-9)	8 (0-9)	6 (0-8)	0.520[c]
Use of MTX, %	64	61.5	66.7	1.000[a]
Dose of PSL, mg/d	5 (2.0-5.0)	5 (2.0-5.0)	5 (2.4-5.3)	0.654[c]
Use of PSL, %	96	92.3	100	1.000[a]
RF titre, IU/ml	72 (29-227)	58 (21-292)	94 (55.5-224)	0.728[c]
Positive rate of RF, %	84	76.9	91.7	0.593[a]
Anti-CCP titre, U/ml	127.1 (35.3-358.3)	112.7 (30.6-399.9)	149.2 (72.5-294.3)	0.936[c]
Positive rate of CCP, %	96	100	91.7	0.480[a]
MMP-3, ng/ml	273 (175.5-455.0)	238.0 (216.0-435.0)	276.5 (110.3-427.5)	0.651[c]

LDA: low disease activity; DAS: disease activity score; CRP: C-reactive protein; MTX: methotrexate; PSL: prednisolone; RF: rheumatoid factor, CCP: cyclic citrullinated peptide, MMP: matrix metalloproteinase a: Fisher's exact test; b: χ^2 test; c: Mann-Whitney U-test.

Table II. Baseline characteristics of patients in LDA and non-LDA groups.

Cytokines	LDA group (n=13)	non-LDA group (n=12)	*p*-value
IL-2 (pg/ml)	8.4 (2.0-8.4)	8.4 (8.1-16.4)	0.596
IL-4 (pg/ml)	0.1 (0.1-1.8)	0.1 (0.1-0.2)	0.192
IL-6 (pg/ml)	100.2 (51.9-145.9)	84.6 (63.4-138.2)	0.765
IL-10 (pg/ml)	8.6 (6.3-12.4)	6.9 (3.7-21.3)	0.568
IL-17A (pg/ml)	23.0 (9.8-37.6)	9.8 (9.8-34.9)	0.759
TNF-α (ml)	9.8 (2.0-11.3)	9.8 (9.5-9.8)	0.731
IFN-γ (pg/ml)	65.8 (14.7-308.9)	120.0 (25.0-387.2)	0.586
CXCL10 (pg/ml)	411.7 (334.4-569.1)	435.5 (117.7-644.1)	0.936

LDA: low disease activity; TNF: tumour necrosis factor; IFN: interferon; CXCL: C-X-C motif chemokine ligand. Mann-Whitney U-test.

T cell cytokines reduced the enhanced expression of CXCL10. This inhibition is likely mediated by IFN-γ. Most importantly, CXCL10 is consistently measurable in the serum of RA patients, thus associated with the therapeutic response of ABT.

CXCL10 is known to play important roles in the perpetuation of inflammation and tissue destruction at inflamed rheumatoid joints. For example, CXCL10 is actively produced by inflammatory stimulation of interferon, IL-1β, and TNF in rheumatoid synovial cells (18, 23, 24), and its level is highly elevated in the rheumatoid synovial fluid of patients, as compared to serum levels (25, 26). Additionally, CXCL10 is involved in homing inflammatory cells, such as activated T cells, monocytes, and NK cells, to inflamed tissue (27-29). Furthermore, CXCL10 can induce RANKL expression in RA synoviocytes and $CD4^+$ T cells (30), suggesting possible involvement in bone resorption at the rheumatoid joint. Previous studies have reported higher levels of CXCL10 in serum or plasma in patients with established RA (31, 32), early RA (33), and untreated early RA (34), as compared to healthy controls. However, the association of CXCL10 with the therapeutic response to ABT has yet to be reported.

There are some limitations in our study. First, the patient population was relatively small and heterogeneous. Thus, the clinical usefulness of CXCL10 should be evaluated in a large-scale

Table III. Change in cytokine parameters after treatment of abatacept in LDA and non-LDA groups.

	LDA group (n=13)			non-LDA group (n=12)		
Cytokines	0W	24W	*p*-value	0W	24W	*p*-value
IL-2 (pg/ml)	8.4 (2.0-8.4)	8.4 (2.0-13.2)	0.201	8.4 (8.1-16.4)	8.4 (7.5-55.1)	0.59
IL-4 (pg/ml)	0.1 (0.1-1.8)	0.4 (0.1-5.3)	0.108	0.1 (0.1-0.2)	0.4 (0.1-6.8)	0.107
IL-6 (pg/ml)	100.2 (51.9-145.9)	19.6 (9.4-55.3)	<0.01	84.6 (63.4-138.2)	37.5 (25.5-66.8)	<0.05
IL-10 (pg/ml)	8.6 (6.3-12.4)	7.1 (3.1-13.5)	<0.05	6.9 (3.7-21.3)	3.6 (2.5-8.8)	<0.01
IL-17A (pg/ml)	23.0 (9.8-37.6)	25.9 (9.8-29.9)	0.477	9.8 (9.8-34.9)	9.8 (9.8-14.5)	0.787
TNF-α (pg/ml)	9.8 (2.0-11.3)	9.8 (2.0-9.8)	0.106	9.8 (9.5-9.8)	9.8 (9.8-13.8)	1.000
IFN-γ (pg/ml)	65.8 (14.7-308.9)	28.8 (7.6-258.4)	0.311	120.0 (25.0-387.2)	29.1 (19.4-87.9)	0.129
CXCL10 (pg/ml)	411.7 (334.4-569.1)	224.4 (134.6-353.0)	<0.01	435.5 (117.7-644.1)	242.7 (51.9-394.0)	0.129

LDA: low disease activity, TNF: tumour necrosis factor, IFN: interferon, CXCL: C-X-C motif chemokine ligand. Wilcoxon's rank test.

study. Second, serum CXCL10 levels at 24 weeks were reduced in the response group, but the levels at baseline were not associated with therapeutic response to ABT. Third, we were not able to assess joint destruction using total sharp score in the two groups. Furthermore, CXCL10 was found to be related to treatment response of ABT treatment. Yet, it is important to clarify whether this association is also related to other biologics.

Based on *in vitro* study, it is likely that IFN-γ and CXCL10 are target molecules of ABT in inflamed rheumatoid joints. In addition, we showed that serum CXCL10 levels may be a possible indicator of therapeutic response to ABT treatment. However, further studies are needed to evaluate the clinical utility of CXCL10 as a disease marker to predict the therapeutic efficacy of biological DMARDs.

Acknowledgments

The authors specially thank Dr Yasunori Shimaoka at Hamawaki Orthopaedic Hospital for the rheumatoid synovial specimens, and Medical & Biological Laboratories Co., Ltd., for an anti-CCP assay kit.

References

1. CROIA C, BURSI R, SUTERA D, PETRELLI F, ALUNNO A, PUXEDDU I: One year in review 2019: pathogenesis of rheumatoid arthritis. *Clin Exp Rheumatol* 2019; 37: 347-57.
2. MCINNES IB, SCHETT G: The pathogenesis of rheumatoid arthritis. *N Engl J Med* 2011; 365: 2205-19.
3. SILVAGNI E, DI BATTISTA M, BONIFACIO AF, ZUCCHI D, GOVERNATO G, SCIRE CA: One year in review 2019: novelties in the treatment of rheumatoid arthritis. *Clin Exp Rheumatol* 2019; 37: 519-34.
4. SMOLEN JS, LANDEWÉ R, BIJLSMA J *et al*.: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. *Ann Rheum Dis* 2017; 76: 960-77.
5. EMERY P: The therapeutic potential of costimulatory blockade with CTLA4Ig in rheumatoid arthritis. *Expert Opin Investig Drugs* 2003; 12: 673-81.
6. SCHIFF M, WEINBLATT ME, VALENTE R *et al*.: Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. *Ann Rheum Dis* 2014; 73: 86-94.
7. SOKOLOVE J, SCHIFF M, FLEISCHMANN R *et al*.: Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial. *Ann Rheum Dis* 2016; 75: 709-14.
8. TAKEUCHI T, KAMEDA H: The Japanese experience with biologic therapies for rheumatoid arthritis. *Nat Rev Rheumatol* 2010; 6: 644-52.
9. D'AGOSTINO MA, WAKEFIELD RJ, BERNER-HAMMER H *et al*.: Value of ultrasonography as a marker of early response to abatacept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results from the APPRAISE study. *Ann Rheum Dis* 2016; 75: 1763-9.
10. GOTTENBERG JE, RAVAUD P, CANTAGREL A *et al*.: Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: data from the 'Orencia and Rheumatoid Arthritis' registry. *Ann Rheum Dis* 2012; 71: 1815-9.
11. LEE JS, AHMAD H, SHIM SC, BAE SC, SONG YW, LEE EY: High proportion of subjective component to the disease activity score is associated with favorable response to abatacept in rheumatoid arthritis. *Patient* 2018; 12: 319-26.
12. PIANTONI S, REGOLA F, SCARSI M, TINCANI A, AIRO P: Circulating follicular helper T cells ($CD4^+CXCR5^+ICOS^+$) decrease in patients with rheumatoid arthritis treated with abatacept. *Clin Exp Rheumatol* 2018; 36: 685.
13. SCARSI M, ZIGLIOLI T, AIRO P: Baseline numbers of circulating CD28-negative T cells may predict clinical response to abatacept in patients with rheumatoid arthritis. *J Rheumatol* 2011; 38: 2105-11.
14. WEISMAN MH, DUREZ P, HALLEGUA D *et al*.: Reduction of inflammatory biomarker response by abatacept in treatment of rheumatoid arthritis. *J Rheumatol* 2006; 33: 2162-6.
15. TWEEHUYSEN L, DEN BROEDER AA, SCHRAA K, NETEA MG, VAN DEN HOOGEN FHJ, JOOSTEN LAB: Predictive value of *ex-vivo* drug-inhibited cytokine production for clinical response to biologic DMARD therapy in rheumatoid arthritis. *Clin Exp Rheumatol* 2019; 37: 367-72.
16. ALETAHA D, NEOGI T, SILMAN AJ *et al*.: 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. *Ann Rheum Dis* 2010; 69: 1580-8.
17. ARNETT FC, EDWORTHY SM, BLOCH DA *et al*.: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. *Arthritis Rheum* 1988; 31: 315-24.
18. LUSTER AD, RAVETCH JV: Biochemical characterization of a gamma interferon-inducible cytokine (IP-10). *J Exp Med* 1987; 166: 1084-97.
19. MARTI L, GOLMIA R, GOLMIA AP *et al*.: Alterations in cytokine profile and dendritic cells subsets in peripheral blood of rheumatoid arthritis patients before and after biologic therapy. *Ann N Y Acad Sci* 2009; 1173: 334-42.
20. SCARSI M, ZANOTTI C, CHIARINI M *et al*.: Reduction of peripheral blood T cells producing IFN-gamma and IL-17 after therapy with abatacept for rheumatoid arthritis. *Clin Exp Rheumatol* 2014; 32: 204-10.
21. ROBERTS CA, DICKINSON AK, TAAMS LS: The interplay between monocytes/macrophages and $CD4^{(+)}$ T cell subsets in rheumatoid arthritis. *Front Immunol* 2015; 6: 571.
22. BRENNAN FM, SMITH NM, OWEN S *et al*.: Resting $CD4^+$ effector memory T cells are precursors of bystander-activated effectors: a surrogate model of rheumatoid arthritis synovial T-cell function. *Arthritis Res Ther* 2008; 10: R36.
23. GROOM JR, LUSTER AD: CXCR3 ligands: redundant, collaborative and antagonistic functions. *Immunol Cell Biol* 2011; 89: 207-15.
24. UENO A, YAMAMURA M, IWAHASHI M *et al*.: The production of CXCR3-agonistic chemokines by synovial fibroblasts from patients with rheumatoid arthritis. *Rheumatol Int* 2005; 25: 361-7.
25. HANAOKA R, KASAMA T, MURAMATSU M *et al*.: A novel mechanism for the regulation of IFN-gamma inducible protein-10 expression in rheumatoid arthritis. *Arthritis Res Ther* 2003; 5: R74-81.
26. PATEL DD, ZACHARIAH JP, WHICHARD LP: CXCR3 and CCR5 ligands in rheumatoid arthritis synovium. *Clin Immunol* 2001; 98: 39-45.
27. LEE EY, LEE ZH, SONG YW: CXCL10 and autoimmune diseases. *Autoimmun Rev* 2009; 8: 379-83.
28. LEE EY, LEE ZH, SONG YW: The interaction between CXCL10 and cytokines in chronic inflammatory arthritis. *Autoimmun Rev* 2013; 12: 554-7.
29. TAUB DD, LLOYD AR, CONLON K *et al*.: Recombinant human interferon-inducible protein 10 is a chemoattractant for human monocytes and T lymphocytes and promotes T cell adhesion to endothelial cells. *J Exp Med* 1993; 177: 1809-14.
30. LEE EY, SEO M, JUHNN YS *et al*.: Potential role and mechanism of IFN-gamma inducible protein-10 on receptor activator of nuclear factor kappa-B ligand (RANKL) expression in rheumatoid arthritis. *Arthritis Res Ther* 2011; 13: R104.
31. ERIKSSON C, RANTAPAA-DAHLQVIST S, SUNDQVIST KG: Changes in chemokines and their receptors in blood during treatment with the TNF inhibitor infliximab in patients with rheumatoid arthritis. *Scand J Rheumatol* 2013; 42: 260-5.
32. HUEBER W, TOMOOKA BH, ZHAO X *et al*.: Proteomic analysis of secreted proteins in early rheumatoid arthritis: anti-citrulline autoreactivity is associated with up regulation of proinflammatory cytokines. *Ann Rheum Dis* 2007; 66: 712-9.
33. KOKKONEN H, SODERSTROM I, ROCKLOV J, HALLMANS G, LEJON K, RANTAPAA DAHLQVIST S: Up-regulation of cytokines and chemokines predates the onset of rheumatoid arthritis. *Arthritis Rheum* 2010; 62: 383-91.
34. PANDYA JM, LUNDELL AC, ANDERSSON K, NORDSTROM I, THEANDER E, RUDIN A: Blood chemokine profile in untreated early rheumatoid arthritis: CXCL10 as a disease activity marker. *Arthritis Res Ther* 2017; 19: 20.